Washington Trust’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$926K Sell
15,273
-182
-1% -$10.6K 0.03% 154
2025
Q4
$834K Buy
15,455
+521
+3% +$25.1K 0.03% 156
2025
Q3
$674K Buy
14,934
+726
+5% +$33.9K 0.02% 174
2025
Q2
$658K Sell
14,208
-224
-2% -$11K 0.02% 171
2025
Q1
$880K Sell
14,432
-8
-0.1% -$466 0.03% 148
2024
Q4
$817K Sell
14,440
-14
-0.1% -$782 0.03% 158
2024
Q3
$748K Sell
14,454
-1,030
-7% -$48.3K 0.03% 167
2024
Q2
$643K Buy
15,484
+304
+2% +$13.6K 0.02% 180
2024
Q1
$823K Sell
15,180
-280
-2% -$14.3K 0.03% 160
2023
Q4
$793K Buy
15,460
+894
+6% +$46.9K 0.03% 161
2023
Q3
$845K Buy
14,566
+81
+0.6% +$4.96K 0.04% 143
2023
Q2
$926K Sell
14,485
-222
-2% -$14.9K 0.04% 140
2023
Q1
$1.02M Sell
14,707
-108
-0.7% -$7.62K 0.05% 138
2022
Q4
$1.07M Sell
14,815
-109
-0.7% -$8.22K 0.05% 138
2022
Q3
$1.06M Buy
14,924
+31
+0.2% +$2.25K 0.05% 128
2022
Q2
$1.15M Sell
14,893
-1,022
-6% -$77.8K 0.05% 125
2022
Q1
$1.16M Sell
15,915
-500
-3% -$33.6K 0.05% 136
2021
Q4
$1.02M Sell
16,415
-8,387
-34% -$492K 0.04% 141
2021
Q3
$1.47M Sell
24,802
-1,936
-7% -$127K 0.04% 162
2021
Q2
$1.79M Sell
26,738
-7,971
-23% -$520K 0.05% 155
2021
Q1
$2.19M Sell
34,709
-2,880
-8% -$179K 0.07% 143
2020
Q4
$2.33M Buy
37,589
+274
+0.7% +$16.8K 0.08% 138
2020
Q3
$2.25M Sell
37,315
-1,342
-3% -$80.8K 0.08% 136
2020
Q2
$2.26M Sell
38,657
-1,969
-5% -$118K 0.09% 130
2020
Q1
$2.27M Sell
40,626
-22,152
-35% -$1.35M 0.11% 128
2019
Q4
$4.03M Buy
62,778
+51,604
+462% +$2.96M 0.16% 121
2019
Q3
$641K Sell
11,174
-3,333
-23% -$157K 0.03% 154
2019
Q2
$657K Buy
14,507
+2,780
+24% +$129K 0.04% 159
2019
Q1
$556K Sell
11,727
-390
-3% -$19.4K 0.03% 164
2018
Q4
$630K Sell
12,117
-5,518
-31% -$296K 0.04% 147
2018
Q3
$1.09M Sell
17,635
-330
-2% -$19.6K 0.06% 132
2018
Q2
$994K Sell
17,965
-125
-0.7% -$6.75K 0.05% 132
2018
Q1
$1.14M Sell
18,090
-225
-1% -$14.5K 0.07% 116
2017
Q4
$1.12M Buy
18,315
+60
+0.3% +$3.75K 0.06% 119
2017
Q3
$1.16M Buy
18,255
+500
+3% +$29.2K 0.07% 117
2017
Q2
$990K Buy
17,755
+268
+2% +$14.6K 0.06% 122
2017
Q1
$951K Sell
17,487
-2,490
-12% -$137K 0.06% 118
2016
Q4
$1.17M Buy
19,977
+525
+3% +$28.7K 0.08% 110
2016
Q3
$1.05M Sell
19,452
-1,195
-6% -$76.8K 0.07% 112
2016
Q2
$1.52M Buy
20,647
+500
+2% +$35.3K 0.1% 108
2016
Q1
$1.29M Sell
20,147
-1,029
-5% -$64.9K 0.09% 111
2015
Q4
$1.46M Sell
21,176
-5,375
-20% -$355K 0.1% 113
2015
Q3
$1.57M Sell
26,551
-1,883
-7% -$119K 0.11% 111
2015
Q2
$1.89M Sell
28,434
-701
-2% -$46.2K 0.12% 108
2015
Q1
$1.88M Sell
29,135
-162
-0.6% -$10.1K 0.12% 107
2014
Q4
$1.73M Buy
29,297
+1,921
+7% +$108K 0.12% 109
2014
Q3
$1.4M Sell
27,376
-210
-0.8% -$10.5K 0.1% 110
2014
Q2
$1.34M Sell
27,586
-3,994
-13% -$197K 0.1% 105
2014
Q1
$1.64M Sell
31,580
-1,808
-5% -$96.2K 0.12% 102
2013
Q4
$1.77M Sell
33,388
-1,763
-5% -$89.8K 0.14% 101
2013
Q3
$1.63M Buy
35,151
+2,788
+9% +$122K 0.13% 101
2013
Q2
$1.45M Buy
+32,363
New +$1.41M 0.12% 100

Other funds holding BMY

Washington Trust's BMY Position: Q1 2026 in Review

Washington Trust reduced its Bristol-Myers Squibb (BMY) stake by 1.2% in Q1 2026, selling an estimated $10.6K and leaving 15,273 shares worth $926K. The position accounts for 0.03% of the portfolio, ranked #154.

Washington Trust first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.03M in Q4 2019. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Washington Trust held 15,273 shares of Bristol-Myers Squibb worth $926K as of Q1 2026.
  • Washington Trust sold 182 Bristol-Myers Squibb shares in Q1 2026, an estimated $10.6K.
  • Bristol-Myers Squibb made up 0.03% of Washington Trust's portfolio in Q1 2026, its #154 holding.
  • Washington Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Washington Trust's Bristol-Myers Squibb position peaked at $4.03M in Q4 2019.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Washington Trust's 13F filing for Q1 2026, filed 6 Apr 2026.